Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty

International Orthopaedics

Volumn 38, Issue 3, 2014, Pages 525-529

  Sasaki, Hiroshi ^a   Ishida, Kazunari ^a   Shibanuma, Nao ^a   Tei, Katsumasa ^a   Tateishi, Hiroomi ^a   Toda, Akihiko ^a   Yamashiro, Yukiko ^a   Matsumoto, Tomoyuki ^b   Kuroda, Ryosuke ^b   Kurosaka, Masahiro ^b  

^a KOBE KAISEI HOSPITAL   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Deep vein thrombosis; Direct factor Xa inhibitor; Edoxaban; Thromboprophylaxis; Total knee arthroplasty

Indexed keywords

EDOXABAN; ENOXAPARIN; FONDAPARINUX; ANTICOAGULANT AGENT; POLYSACCHARIDE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; FEMALE; GENERAL ANESTHESIA; HUMAN; KNEE OSTEOARTHRITIS; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; THROMBOSIS PREVENTION; TOTAL KNEE REPLACEMENT; COMPARATIVE STUDY; DOSE RESPONSE; INCIDENCE; KNEE; KNEE ARTHROPLASTY; OSTEOARTHRITIS, KNEE; RETROSPECTIVE STUDY; SURGERY; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, KNEE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; FEMALE; HUMANS; INCIDENCE; KNEE JOINT; MALE; OSTEOARTHRITIS, KNEE; POLYSACCHARIDES; PYRIDINES; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84894539034     PISSN: 03412695     EISSN: 14325195     Source Type: Journal    
DOI: 10.1007/s00264-013-2132-x     Document Type: Article

References (19)

1. Cohen AT (2012) Long-term benefits of preventing venous thromboembolic events. Curr Med Res Opin 28(6):877-889. doi: 10.1185/03007995.2012.688737
2. McRae SJ, Ginsberg JS (2004) Initial treatment of venous thromboembolism. Circulation 110(9 Suppl 1):I3-I9. doi: 10.1161/01.CIR.0000140904.52752.0c
3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):381S-453S. doi: 10.1378/chest.08-0656
4. Weinmann EE, Salzman EW (1994) Deep-vein thrombosis. N Engl J Med 331(24):1630-1641. doi: 10.1056/NEJM199412153312407
5. Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG (2004) Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl):338S-400S. doi: 10.1378/chest.126.3-suppl.338S
6. Stulberg BN, Insall JN, Williams GW, Ghelman B (1984) Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am 66(2):194-201
7. Westrich GH, Sculco TP (1996) Prophylaxis against deep venous thrombosis after total knee arthroplasty. Pneumatic plantar compression and aspirin compared with aspirin alone. J Bone Joint Surg Am 78(6):826-834
8. Beyer-Westendorf J, Lützner J, Donath L, Radke OC, Kuhlisch E, Hartmann A, Weiss N, Werth S (2012) Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ORTHO-TEP registry. J Thromb Haemost 10(10):2045-2052. doi: 10.1111/j.1538-7836. 2012.04877.x
9. Falck-Ytter Y (2012) Prevention of VTE in Orthopedic Surgery PatientsPrevention of VTE in Orthopedic Surgery PatientsAntithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST Journal 141 (2-suppl):e278S. doi: 10.1378/chest.11-2404
10. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI (2010) Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost 104(3):642-649. doi: 10.1160/TH10-02-0142
11. Fuji T (2010) Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARES E-3 trialls (abstrct). Paper presented at the Pathophysiol Haemost Thromb
12. Bounameaux H, Cirafici P, de Moerloose P, Schneider PA, Slosman D, Reber G, Unger PF (1991) Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet 337(8735):196-200
13. Fuji T, Fujita S, Tachibana S, Kawai Y (2010) A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 8(11):2458-2468. doi: 10.1111/j.1538-7836.2010.04021.x
14. Morishima Y, Honda Y, Kamisato C, Tsuji N, Kita A, Edo N, Shibano T (2012) Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. Thromb Res 130(3):514-519. doi: 10.1016/j.thromres.2012.05.008
15. Turpie AG (2007) Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27(6):1238-1247. doi: 10.1161/ATVBAHA.107.139402
16. Piccini JP, Lopes RD, Mahaffey KW (2010) Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Curr Opin Cardiol 25(4):312-320. doi: 10.1097/HCO.0b013e32833a524f
17. Karnicki K, McBane RD 2nd, Miller RS, Leadley RJ Jr, Morser J, Owen WG, Chesebro JH (2004) Inhibition and reversal of platelet-rich arterial thrombus in vivo: direct vs. indirect factor Xa inhibition. J Thromb Haemost 2(12):2162-2169. doi: 10.1111/j.1538-7836.2004.01040.x
18. Rezaie AR (2001) Prothrombin protects factor Xa in the prothrombinase complex from inhibition by the heparin-antithrombin complex. Blood 97(8):2308-2313
19. Turpie AG (2008) New oral anticoagulants in atrial fibrillation. Eur Heart J 29(2):155-165. doi: 10.1093/eurheartj/ehm575